Cyclacel To Test Higher Doses Of Fadraciclib In Solid Tumor Patients

  • Cyclacel Pharmaceuticals Inc CYCC is adding two dose levels in a protocol amendment to test higher doses of oral fadraciclib before determining the recommended Phase 2 dose anticipated in 2H of 2022, citing the absence of dose-limiting toxicities.
  • Fifteen patients with advanced solid tumors and lymphomas were treated with oral fadraciclib at all five doses.
  • In the first oral treatment cycle with fadraciclib, a cutaneous T cell lymphoma patient achieved partial response (PR).
  • A patient with a peripheral T cell lymphoma achieved a 38% reduction in target lesions.
  • An endometrial cancer patient achieved stable disease with a 15% reduction of target lesions after the first oral treatment cycle. In an earlier study of intravenous fadraciclib as monotherapy, a patient with MCL1 amplified endometrial cancer achieved confirmed complete response (CR) and remains on study after 2.5 years of treatment.
  • A pancreatic cancer patient achieved stable disease by the confirmatory scan for five oral treatment cycles.
  • For CYC140, no dose-limiting toxicities were observed to date in the Phase 1/2 study of oral CYC140.
  • An ovarian cancer patient in 140-101 achieved stable disease with tumor shrinkage after the first cycle.
  • Price Action: CYCC shares are down 28.4% at $1.06 during the market session on the last check Thursday.

Posted In: BriefsBiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.